| 1 |
Wu J, Pei F, Zhou L, et al. The efficacy and safety of thymosin alpha1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial [J]. BMJ, 2025, 388: e082583.
|
| 2 |
Moore AR, Zheng H, Ganesan A, et al. A consensus immune dysregulation framework for sepsis and critical illnesses [J]. Nat Med, 2025, 31(12): 4084-4096.
|
| 3 |
Giamarellos-Bourboulis EJ, Kotsaki A, Kotsamidi I, et al. Precision immunotherapy to improve sepsis outcomes: the ImmunoSep randomized clinical trial [J]. JAMA, 2026, 335(9): 775-786.
|
| 4 |
Kox M, Bauer M, Bos LDJ, et al. The immunology of sepsis: translating new insights into clinical practice [J]. Nat Rev Nephrol, 2026, 22(1): 30-49.
|
| 5 |
Deinhardt-Emmer S, Chousterman BG, Schefold JC, et al. Sepsis in patients who are immunocompromised: diagnostic challenges and future therapies [J]. Lancet Respir Med, 2025, 13(7): 623-637.
|
| 6 |
Gu B, Zhou Y, Nie Y, et al. Efficacy of thymosin alpha1 for sepsis: a systematic review and meta-analysis of randomized controlled trials [J]. Front Cell Infect Microbiol, 2025, 15: 1673959.
|
| 7 |
Powers JH III, Natanson C. Immunotherapies for sepsis and the impact of study design [J]. BMJ, 2025, 388: r48.
|
| 8 |
Leventogiannis K, Kyriazopoulou E, Antonakos N, et al. Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial [J]. Cell Rep Med, 2022, 3(11): 100817.
|
| 9 |
脓毒症免疫调理治疗临床研究协作组. 乌司他丁、α1胸腺肽联合治疗严重脓毒症——一种新的免疫调理治疗方法的临床研究 [J]. 中华医学杂志, 2007, 87(7): 451-457.
|
| 10 |
Liu S, Yao C, Xie J, et al. Effect of an Herbal-Based Injection on 28-day mortality in patients with sepsis: the EXIT-SEP randomized clinical trial [J]. JAMA Intern Med, 2023, 183(7): 647-655.
|
| 11 |
Lou X, Chen H, Shi N, et al. Treatment effects of Xuebijing Injection in patients with sepsis by clinical phenotype: a post hoc analysis of the EXIT-SEP trial [J]. EClinicalMedicine, 2025, 86: 103341.
|
| 12 |
Seymour CW, Kennedy JN, Wang S, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis [J]. JAMA, 2019, 321(20): 2003-2017.
|
| 13 |
Davenport EE, Burnham KL, Radhakrishnan J, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study [J]. Lancet Respir Med, 2016, 4(4): 259-271.
|
| 14 |
Zheng H, Rao AM, Dermadi D, et al. Multi-cohort analysis of host immune response identifies conserved protective and detrimental modules associated with severity across viruses [J]. Immunity, 2021, 54(4): 753-768 e755.
|
| 15 |
Sweeney TE, Azad TD, Donato M, et al. Unsupervised analysis of transcriptomics in bacterial sepsis across multiple datasets reveals three robust clusters [J]. Crit Care Med, 2018, 46(6): 915-925.
|
| 16 |
Scicluna BP, Van Vught LA, Zwinderman AH, et al. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study [J]. Lancet Respir Med, 2017, 5(10): 816-826.
|
| 17 |
Cano-Gamez K, Burnham KL, Goh C, et al. An immune dysfunction score for stratification of patients with acute infection based on whole-blood gene expression [J]. Sci Transl Med, 2022, 14(669): eabq4433.
|
| 18 |
Yao L, Rey DA, Bulgarelli L, et al. Gene expression scoring of immune activity levels for precision use of Hydrocortisone in vasodilatory shock [J]. Shock, 2022, 57(3): 384-391.
|
| 19 |
Wong HR, Cvijanovich N, Lin R, et al. Identification of pediatric septic shock subclasses based on genome-wide expression profiling [J]. BMC Med, 2009, 7: 34.
|
| 20 |
Wong HR, Cvijanovich NZ, Anas N, et al. Developing a clinically feasible personalized medicine approach to pediatric septic shock [J]. Am J Respir Crit Care Med, 2015, 191(3): 309-315.
|
| 21 |
Cajander S, Kox M, Scicluna BP, et al. Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine [J]. Lancet Respir Med, 2024, 12(4): 305-322.
|
| 22 |
Scicluna BP, Cano-Gamez K, Burnham KL, et al. A consensus blood transcriptomic framework for sepsis [J]. Nat Med, 2025, 31(12): 4119-4130.
|
| 23 |
Pei F, Liu N, Yuan J, et al. Identification of distinct immune subtypes in sepsis through dual immunomarker trajectory [J]. Ann Intensive Care, 2026, 16: 100039.
|
| 24 |
Nagin DS, Jones BL, Passos VL, et al. Group-based multi-trajectory modeling [J]. Stat Methods Med Res, 2018, 27(7): 2015-2023.
|
| 25 |
Shankar-Hari M, Calandra T, Soares MP, et al. Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies [J]. Lancet Respir Med, 2024, 12(4): 323-336.
|
| 26 |
Butterfield LH, Najjar YG. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations [J]. Nat Rev Immunol, 2024, 24(6): 399-416.
|